Physiol. Genomics Watch the video to learn how APS reaches out to developing nations.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Physiol. Genomics 34: 239-242, 2008. First published June 10, 2008; doi:10.1152/physiolgenomics.90254.2008
1094-8341/08 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
34/3/239    most recent
90254.2008v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Latronico, M. V. G.
Right arrow Articles by Condorelli, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Latronico, M. V. G.
Right arrow Articles by Condorelli, G.
Received 6 May 2008; accepted in final form 5 June 2008.
Physiological Genomics 34:239-242 (2008)
1094-8341/08 $8.00 © 2008 American Physiological Society

Review

MicroRNA and cardiac pathologies

Michael V. G. Latronico 1, Daniele Catalucci 1,2 and Gianluigi Condorelli 1,2,3

1 Laboratory of Genetic and Molecular Cardiology, Science and Technology Pole, Istituto di Ricovero e Cura a Carattere Scientifico MultiMedica, Milan, Italy
2 Institute of Biomedical Technologies, Italian National Research Council (CNR), Milan, Italy
3 Division of Cardiology, Department of Medicine, University of California San Diego, La Jolla, California

MicroRNA has been shown to be essential for correct cardiovascular development and physiology in a number of recent reports. Studies have also started to characterize the link between specific microRNAs and aspects of pathogenesis—such as chamber morphogenesis, conduction, and contraction—and between microRNA expression signatures and pathological cardiac phenotypes—such as hypertrophy, ischemic cardiomyopathy, dilated cardiomyopathy, and aortic stenosis. Congenital anomalies of the heart may also be associated with the dysregulation of specific microRNAs. Here we report on the latest findings.

hypertrophy; cardiomyopathy; cardiac insufficiency




This article has been cited by other articles:


Home page
Nucleic Acids ResHome page
P. Alexiou, T. Vergoulis, M. Gleditzsch, G. Prekas, T. Dalamagas, M. Megraw, I. Grosse, T. Sellis, and A. G. Hatzigeorgiou
miRGen 2.0: a database of microRNA genomic information and regulation
Nucleic Acids Res., November 17, 2009; (2009) gkp888v2.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
M. Liang, Y. Liu, D. Mladinov, A. W. Cowley Jr., H. Trivedi, Y. Fang, X. Xu, X. Ding, and Z. Tian
MicroRNA: a new frontier in kidney and blood pressure research
Am J Physiol Renal Physiol, September 1, 2009; 297(3): F553 - F558.
[Abstract] [Full Text] [PDF]


Home page
Physiol. GenomicsHome page
M. Liang
MicroRNA: a new entrance to the broad paradigm of systems molecular medicine
Physiol Genomics, July 9, 2009; 38(2): 113 - 115.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.